Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: What a fly and mouse model can teach us

Learning and Memory

Volumn 21, Issue 10, 2014, Pages 543-555

  Santos, Ana Rita ^a,b   Kanellopoulos, Alexandros K ^a,b   Bagni, Claudia ^a,b,c  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; MESSENGER RNA; DROSOPHILA PROTEIN; FMR1 PROTEIN, DROSOPHILA; FMR1 PROTEIN, MOUSE;

ANXIETY; AUTISM; BEHAVIOR DISORDER; BRAIN DEVELOPMENT; COGNITIVE DEFECT; DEVELOPMENTAL DISORDER; DISEASE MODEL; DROSOPHILA MELANOGASTER; FMRL GENE; FRAGILE X SYNDROME; GENE; GENE MUTATION; HYPERACTIVITY; LEARNING DISORDER; MOUSE; NEURODEVELOPMENTAL DELAY; NONHUMAN; REVIEW; ANIMAL; CIRCADIAN RHYTHM; GENETICS; HUMAN; KNOCKOUT MOUSE; LEARNING; PATHOPHYSIOLOGY; PHYSIOLOGY; SENSORY GATING; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR;

ANIMALS; ANXIETY; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; LEARNING; MICE; MICE, KNOCKOUT; SENSORY GATING; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR;

EID: 84907713894     PISSN: 10720502     EISSN: 15495485     Source Type: Journal    
DOI: 10.1101/lm.035956.114     Document Type: Review

References (195)

1. Antion MD, Merhav M, Hoeffer CA, Reis G, Kozma SC, Thomas G, Schuman EM, Rosenblum K, Klann E. 2008. Removal of S6K1 and S6K2 leads to divergent alterations in learning, memory, and synaptic plasticity. Learn Mem 15: 29-38.
2. Bagni C, Greenough WT. 2005. From mRNP trafficking to spine dysmorphogenesis: the roots of Fragile X syndrome. Nat Rev Neurosci 6: 376-387.
3. Bagni C, Tassone F, Neri G, Hagerman R. 2012. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest 122: 4314-4322.
4. Baker KB, Wray SP, Ritter R, Mason S, Lanthorn TH, Savelieva KV. 2010. Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments. Genes Brain Behav 9: 562-574.
5. Banerjee P, Nayar S, Hebbar S, Fox CF, Jacobs MC, Park JH, Fernandes JJ, Dockendorff TC. 2007. Substitution of critical isoleucines in the KH domains of Drosophila fragile X protein results in partial loss-of-function phenotypes. Genetics 175: 1241-1250.
6. Bear MF, Huber KM, Warren ST. 2004. The mGluR theory of fragile X mental retardation. Trends Neurosci 27: 370-377.
7. Belvin MP, Zhou H, Yin JC. 1999. The Drosophila dCREB2 gene affects the circadian clock. Neuron 22: 777-787.
8. Berry-Kravis E. 2002. Epilepsy in Fragile X syndrome. Dev Med Child Neurol 44: 724-728.
9. Berry-Kravis E. 2014. Mechanism-based treatments in neurodevelopmental disorders: Fragile X syndrome. Pediatr Neurol 50: 297-302.
10. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchison J, Snape M, Tranfaglia M, Nguyen DV, et al. 2009. A pilot open label, single dose trial of fenobam in adults with Fragile X syndrome. J Med Genet 46: 266-271.
11. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, et al. 2012. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 4: 152ra127.
12. Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC, Murphy JP, Pierre P, Klann E. 2012. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 76: 325-337.
13. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM. 2009. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 46: 94-102.
14. Bolduc FV, Bell K, Cox H, Broadie KS, Tully T. 2008. Excess protein synthesis in Drosophila fragile Xmutants impairs long-term memory. Nat Neurosci 11: 1143-1145.
15. Bolduc FV, Valente D, Mitra P, Tully T. 2010. An assay for social interaction in Drosophila Fragile X mutants. Fly (Austin) 4: 216-225.
16. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L. 1978. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15: 339-343.
17. Brockhaus-Dumke A, Schultze-Lutter F, Mueller R, Tendolkar I, Bechdolf A, Pukrop R, Klosterkoetter J, Ruhrmann S. 2008. Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol Psychiatry 64: 376-384.
18. Bushey D, Tononi G, Cirelli C. 2009. The Drosophila fragile X mental retardation gene regulates sleep need. J Neurosci 29: 1948-1961.
19. Busquets-Garcia A, Gomis-Gonzalez M, Guegan T, Agustin-Pavon C, Pastor A, Mato S, Perez-Samartin A, Matute C, de la Torre R, Dierssen M, et al. 2013. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med 19: 603-607.
20. Busquets-Garcia A, Maldonado R, Ozaita A. 2014. New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model. Int J Biochem Cell Biol 53C: 121-126.
21. Chang DC. 2006. Neural circuits underlying circadian behavior in Drosophila melanogaster. Behav Processes 71: 211-225.
22. Chang S, Bray SM, Li Z, Zarnescu DC, He C, Jin P, Warren ST. 2008. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol 4: 256-263.
23. Chen L, Toth M. 2001. Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience 103: 1043-1050.
24. Choi CH, McBride SM, Schoenfeld BP, Liebelt DA, Ferreiro D, Ferrick NJ, Hinchey P, Kollaros M, Rudominer RL, Terlizzi AM, et al. 2010. Age-dependent cognitive impairment in a Drosophila fragile X model and its pharmacological rescue. Biogerontology 11: 347-362.
25. Coffee RL Jr, Tessier CR, Woodruff EA III, Broadie K. 2010. Fragile X mental retardation protein has a unique, evolutionarily conserved neuronal function not shared with FXR1P or FXR2P. Dis Model Mech 3: 471-485.
26. Coffee RL Jr, Williamson AJ, Adkins CM, Gray MC, Page TL, Broadie K. 2012. In vivo neuronal function of the fragile X mental retardation protein is regulated by phosphorylation. Hum Mol Genet 21: 900-915.
27. Cordeiro L, Ballinger E, Hagerman R, Hessl D. 2011. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord 3: 57-67.
28. Curzon P, Kim DJ, Decker MW. 1994. Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat. Pharmacol Biochem Behav 49: 877-882.
29. Curzon P, Rustay NR, Browman KE. 2009. Cued and contextual fear conditioning for rodents. In Methods of behavior analysis in neuroscience (ed. Buccafusco JJ), pp. 19-37, chapter 2. CRC Press, Boca Raton, FL.
30. Dalley JW, Cardinal RN, Robbins TW. 2004. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 28: 771-784.
31. Dansie LE, Phommahaxay K, Okusanya AG, Uwadia J, Huang M, Rotschafer SE, Razak KA, Ethell DW, Ethell IM. 2013. Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice. Neuroscience 246: 186-198.
32. Darnell JC, Klann E. 2013. The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci 16: 1530-1536.
33. Davis RL. 1993. Mushroom bodies and Drosophila learning. Neuron 11: 1-14.
34. De Boulle K, Verkerk AJ, Reyniers E, Vits L, Hendrickx J, Van Roy B, Van den Bos F, de Graaff E, Oostra BA, Willems PJ. 1993. A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat Genet 3: 31-35.
35. De Rubeis S, Fernandez E, Buzzi A, Di Marino D, Bagni C. 2012. Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis. Adv Exp Med Biol 970: 517-551.
36. De Rubeis S, Pasciuto E, Li KW, Fernandez E, Di Marino D, Buzzi A, Ostroff LE, Klann E, Zwartkruis FJ, Komiyama NH, et al. 2013. CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation. Neuron 79: 1169-1182.
37. de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, Oostra BA, Willemsen R. 2008. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 31: 127-132.
38. D'Hooge R, Nagels G, Franck F, Bakker CE, Reyniers E, Storm K, Kooy RF, Oostra BA, Willems PJ, De Deyn PP. 1997. Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience 76: 367-376.
39. D'Hulst C, Kooy RF. 2007. The GABAA receptor: a novel target for treatment of fragile X? Trends Neurosci 30: 425-431.
40. Dockendorff TC, Su HS, McBride SM, Yang Z, Choi CH, Siwicki KK, Sehgal A, Jongens TA. 2002. Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron 34: 973-984.
41. Dolan BM, Duron SG, Campbell DA, Vollrath B, Rao BS, Ko HY, Lin GG, Govindarajan A, Choi SY, Tonegawa S. 2013. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc Natl Acad Sci 110: 5671-5676.
42. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF. 2007. Correction of fragile X syndrome in mice. Neuron 56: 955-962.
43. Doll CA, Broadie K. 2014. Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models. Front Cell Neurosci 8: 30.
44. Doyle M, Kiebler MA. 2012. A numbers game underpins cytoplasmic mRNA transport. Nat Cell Biol 14: 333-335.
45. The Dutch-Belgian Fragile X Consortium. 1994. Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78: 23-33.
46. El Idrissi A, Boukarrou L, Dokin C, Brown WT. 2009. Taurine improves congestive functions in a mouse model of fragile X syndrome. Adv Exp Med Biol 643: 191-198.
47. Fernandez E, Rajan N, Bagni C. 2013. The FMRP regulon: from targets to disease convergence. Front Neurosci 7: 191.
48. Ferrari F, Mercaldo V, Piccoli G, Sala C, Cannata S, Achsel T, Bagni C. 2007. The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines. Mol Cell Neurosci 34: 343-354.
49. Fiala JC, Spacek J, Harris KM. 2002. Dendritic spine pathology: cause or consequence of neurological disorders? Brain Res Brain Res Rev 39: 29-54.
50. Frankland PW, Wang Y, Rosner B, Shimizu T, Balleine BW, Dykens EM, Ornitz EM, Silva AJ. 2004. Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. Mol Psychiatry 9: 417-425.
51. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, Georgieva L, Rees E, Palta P, Ruderfer DM, et al. 2014. De novo mutations in schizophrenia implicate synaptic networks. Nature 506: 179-184.
52. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJ, Holden JJ, Fenwick RG Jr, Warren ST, et al. 1991. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67: 1047-1058.
53. Galvez R, Greenough WT. 2005. Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. Am J Med Genet A 135: 155-160.
54. Galy A, Schenck A, Sahin HB, Qurashi A, Sahel JA, Diebold C, Giangrande A. 2011. CYFIP dependent actin remodeling controls specific aspects of Drosophila eye morphogenesis. Dev Biol 359: 37-46.
55. Gao FB. 2002. Understanding fragile X syndrome: in sights from retarded flies. Neuron 34: 859-862.
56. Garrido-Mesa N, Zarzuelo A, Galvez J. 2013. What is behind the nonantibiotic properties of minocycline? Pharmacol Res 67: 18-30.
57. Gatto CL, Broadie K. 2008. Temporal requirements of the fragile X mental retardation protein in the regulation of synaptic structure. Development 135: 2637-2648.
58. Gatto CL, Broadie K. 2009. Temporal requirements of the fragile x mental retardation protein in modulating circadian clock circuit synaptic architecture. Front Neural Circuits 3: 8.
59. Gatto CL, Pereira D, Broadie K. 2014. GABAergic circuit dysfunction in the Drosophila Fragile X syndrome model. Neurobiol Dis 65: 142-159.
60. Geurts HM, Corbett B, Solomon M. 2009. The paradox of cognitive flexibility in autism. Trends Cogn Sci 13: 74-82.
61. Godfraind JM, Reyniers E, De Boulle K, D'Hooge R, De Deyn PP, Bakker CE, Oostra BA, Kooy RF, Willems PJ. 1996. Long-term potentiation in the hippocampus of fragile X knockout mice. Am J Med Genet 64: 246-251.
62. Goebel-Goody SM, Wilson-Wallis ED, Royston S, Tagliatela SM, Naegele JR, Lombroso PJ. 2012. Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav 11: 586-600.
63. Gomez-Mancilla B, Berry-Kravis E, Hagerman R, von Raison F, Apostol G, Ufer M, Gasparini F, Jacquemont S. 2014. Development of mavoglurant and its potential for the treatment of fragile X syndrome. Expert Opin Investig Drugs 23: 125-134.
64. Gould EL, Loesch DZ, Martin MJ, Hagerman RJ, Armstrong SM, Huggins RM. 2000. Melatonin profiles and sleep characteristics in boys with fragile X syndrome: a preliminary study. Am J Med Genet 95: 307-315.
65. Greenspan RJ, Ferveur JF. 2000. Courtship in Drosophila. Annu Rev Genet 34: 205-232.
66. Gross C, Berry-Kravis EM, Bassell GJ. 2012. Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychopharmacology 37: 178-195.
67. Guo W, Allan AM, Zong R, Zhang L, Johnson EB, Schaller EG, Murthy AC, Goggin SL, Eisch AJ, Oostra BA, et al. 2011. Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning. Nat Med 17: 559-565.
68. Guo W, Murthy AC, Zhang L, Johnson EB, Schaller EG, Allan AM, Zhao X. 2012. Inhibition of GSK3beta improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum Mol Genet 21: 681-691.
69. Hagerman R. 1997. Fragile X: treatment of hyperactivity. Pediatrics 99: 753.
70. Hagerman RJ, Staley LW, O'Conner R, Lugenbeel K, Nelson D, McLean SD, Taylor A. 1996. Learning-disabled males with a fragile X CGG expansion in the upper premutation size range. Pediatrics 97: 122-126.
71. Hagerman R, Lauterborn J, Au J, Berry-Kravis E. 2012. Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ 54: 297-335.
72. Hagerman RJ, Des-Portes V, Gasparini F, Jacquemont S, Gomez-Mancilla B. 2014. Translating molecular advances in fragile X syndrome into therapy: a review. J Clin Psychiatry 75: e294-e307.
73. Hall JC. 1994. The mating of a fly. Science 264: 1702-1714.
74. Hammer TB, Oranje B, Skimminge A, Aggernaes B, Ebdrup BH, Glenthoj B, Baare W. 2013. Structural brain correlates of sensorimotor gating in antipsychotic-naive men with first-episode schizophrenia. J Psychiatry Neurosci 38: 34-42.
75. Hayashi ML, Choi SY, Rao BS, Jung HY, Lee HK, Zhang D, Chattarji S, Kirkwood A, Tonegawa S. 2004. Altered cortical synaptic morphology and impaired memory consolidation in forebrain-specific dominant-negative PAK transgenic mice. Neuron 42: 773-787.
76. Hayashi ML, Rao BS, Seo JS, Choi HS, Dolan BM, Choi SY, Chattarji S, Tonegawa S. 2007. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci 104: 11489-11494.
77. Hecht F, Sutherland GR. 1985. Detection of fragile sites on human chromosomes. Clin Genet 28: 95-96.
78. Helfrich-Forster C. 2005. Neurobiology of the fruit fly's circadian clock. Genes Brain Behav 4: 65-76.
79. Ho VM, Lee JA, Martin KC. 2011. The cell biology of synaptic plasticity. Science 334: 623-628.
80. Hornberg H, Holt C. 2013. RNA-binding proteins and translational regulation in axons and growth cones. Front Neurosci 7: 81.
81. Huber KM, Gallagher SM, Warren ST, Bear MF. 2002. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci 99: 7746-7750.
82. Inoue S, Shimoda M, Nishinokubi I, Siomi MC, Okamura M, Nakamura A, Kobayashi S, Ishida N, Siomi H. 2002. A role for the Drosophila fragile X-related gene in circadian output. Curr Biol 12: 1331-1335.
83. Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J, Yamrom B, Lee YH, Narzisi G, Leotta A, et al. 2012. De novo gene disruptions in children on the autistic spectrum. Neuron 74: 285-299.
84. Jacquemont S, Berry-Kravis E, Hagerman R, von Raison F, Gasparini F, Apostol G, Ufer M, Des Portes V, Gomez-Mancilla B. 2014. The challenges of clinical trials in fragile X syndrome. Psychopharmacology 231: 1237-1250.
85. Janusz A, Milek J, Perycz M, Pacini L, Bagni C, Kaczmarek L, Dziembowska M. 2013. The Fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses. J Neurosci 33: 18234-18241.
86. Joiner WJ, Crocker A, White BH, Sehgal A. 2006. Sleep in Drosophila is regulated by adult mushroom bodies. Nature 441: 757-760.
87. Jung H, Yoon BC, Holt CE. 2012. Axonal mRNA localization and local protein synthesis in nervous system assembly, maintenance and repair. Nat Rev Neurosci 13: 308-324.
88. Kanellopoulos AK, Semelidou O, Kotini AG, Anezaki M, Skoulakis EM. 2012. Learning and memory deficits consequent to reduction of the fragile X mental retardation protein result from metabotropic glutamate receptor-mediated inhibition of cAMP signaling in Drosophila. J Neurosci 32: 13111-13124.
89. Kang H, Schuman EM. 1996. A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. Science 273: 1402-1406.
90. Kelleher RJ III, Bear MF. 2008. The autistic neuron: troubled translation? Cell 135: 401-406.
91. King M, Bottomley C, Bellon-Saameno J, Torres-Gonzalez F, Svab I, Rotar D, Xavier M, Nazareth I. 2013. Predicting onset of major depression in general practice attendees in Europe: extending the application of the predict Drisk algorithm from 12 to 24 months. Psychol Med 43: 1929-1939.
92. Kobayashi K, Kuroda S, Fukata M, Nakamura T, Nagase T, Nomura N, Matsuura Y, Yoshida-Kubomura N, Iwamatsu A, Kaibuchi K. 1998. p140Sra-1 (specifically Rac1-associated protein) is a novel specific target for Rac1 small GTPase. J Biol Chem 273: 291-295.
93. Kooy RF, D'Hooge R, Reyniers E, Bakker CE, Nagels G, De Boulle K, Storm K, Clincke G, De Deyn PP, Oostra BA, et al. 1996. Transgenic mouse model for the fragile X syndrome. Am J Med Genet 64: 241-245.
94. Krueger DD, Bear MF. 2011. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 62: 411-429.
95. Krueger DD, Osterweil EK, Chen SP, Tye LD, Bear MF. 2011. Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc Natl Acad Sci 108: 2587-2592.
96. Lai JK, Sobala-Drozdowski M, Zhou L, Doering LC, Faure PA, Foster JA. 2014. Temporal and spectral differences in the ultrasonic vocalizations of fragile X knock out mice during postnatal development. Behav Brain Res 259: 119-130.
97. Larson J, Jessen RE, Kim D, Fine AK, du Hoffmann J. 2005. Age-dependent and selective impairment of long-term potentiation in the anterior piriform cortex of mice lacking the fragile X mental retardation protein. J Neurosci 25: 9460-9469.
98. Lee A, Li W, Xu K, Bogert BA, Su K, Gao FB. 2003. Control of dendritic development by the Drosophila fragile X-related gene involves the small GTPase Rac1. Development 130: 5543-5552.
99. Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, et al. 2013. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr 34: 147-155.
100. Liu ZH, Smith CB. 2009. Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome. Neurosci Lett 454: 62-66.
101. Liu ZH, Chuang DM, Smith CB. 2011. Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol 14: 618-630.
102. Lugenbeel KA, Peier AM, Carson NL, Chudley AE, Nelson DL. 1995. Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndrome. Nat Genet 10: 483-485.
103. Mandel JL, Biancalana V. 2004. Fragile X mental retardation syndrome: from pathogenesis to diagnostic issues. Growth Horm IGF Res 14 Suppl A: S158-S165.
104. McBride SM, Giuliani G, Choi C, Krause P, Correale D, Watson K, Baker G, Siwicki KK. 1999. Mushroom body ablation impairs short-term memory and long-term memory of courtship conditioning in Drosophila melanogaster. Neuron 24: 967-977.
105. McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, Sehgal A, Siwicki KK, Dockendorff TC, Nguyen HT, et al. 2005. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45: 753-764.
106. McNaughton CH, Moon J, Strawderman MS, Maclean KN, Evans J, Strupp BJ. 2008. Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome. Behav Neurosci 122: 293-300.
107. Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L. 2012. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74: 49-56.
108. Michaluk P, Wawrzyniak M, Alot P, Szczot M, Wyrembek P, Mercik K, Medvedev N, Wilczek E, De Roo M, Zuschratter W, et al. 2011. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci 124: 3369-3380.
109. Michel CI, Kraft R, Restifo LL. 2004. Defective neuronal development in the mushroom bodies of Drosophila fragile X mental retardation 1 mutants. J Neurosci 24: 5798-5809.
110. Mili S, Moissoglu K, Macara IG. 2008. Genome-wide screen reveals APCassociated RNAs enriched in cell protrusions. Nature 453: 115-119.
111. Min WW, Yuskaitis CJ, Yan Q, Sikorski C, Chen S, Jope RS, Bauchwitz RP. 2009. Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 56: 463-472.
112. Mines MA, Yuskaitis CJ, King MK, Beurel E, Jope RS. 2010. GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One 5: e9706.
113. Mineur YS, Sluyter F, de Wit S, Oostra BA, Crusio WE. 2002. Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus 12: 39-46.
114. Mineur YS, Huynh LX, Crusio WE. 2006. Social behavior deficits in the Fmr1 mutant mouse. Behav Brain Res 168: 172-175.
115. Moon J, Ota KT, Driscoll LL, Levitsky DA, Strupp BJ. 2008. A mouse model of fragile X syndrome exhibits heightened arousal and/or emotion following errors or reversal of contingencies. Dev Psychobiol 50: 473-485.
116. Morales J, Hiesinger PR, Schroeder AJ, Kume K, Verstreken P, Jackson FR, Nelson DL, Hassan BA. 2002. Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron 34: 961-972.
117. Moressis A, Friedrich AR, Pavlopoulos E, Davis RL, Skoulakis EM. 2009. A dual role for the adaptor protein DRK in Drosophila olfactory learning and memory. J Neurosci 29: 2611-2625.
118. Morris RG, Garrud P, Rawlins JN, O'Keefe J. 1982. Place navigation impaired in rats with hippocampal lesions. Nature 297: 681-683.
119. Moy SS, Nadler JJ, Perez A, Barbaro RP, Johns JM, Magnuson TR, Piven J, Crawley JN. 2004. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav 3: 287-302.
120. Musumeci SA, Hagerman RJ, Ferri R, Bosco P, Dalla Bernardina B, Tassinari CA, De Sarro GB, Elia M. 1999. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 40: 1092-1099.
121. Musumeci SA, Bosco P, Calabrese G, Bakker C, De Sarro GB, Elia M, Ferri R, Oostra BA. 2000. Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 41: 19-23.
122. Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zalfa F, De Rubeis S, Di Marino D, Mohr E, Massimi M, Falconi M, et al. 2008. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 134: 1042-1054.
123. Nielsen DM, Derber WJ, McClellan DA, Crnic LS. 2002. Alterations in the auditory startle response in Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Res 927: 8-17.
124. Nitabach MN, Wu Y, Sheeba V, Lemon WC, Strumbos J, Zelensky PK, White BH, Holmes TC. 2006. Electrical hyperexcitation of lateral ventral pacemaker neurons desynchronizes downstream circadian oscillators in the fly circadian circuit and induces multiple behavioral periods. J Neurosci 26: 479-489.
125. Nosyreva ED, Huber KM. 2006. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J Neurophysiol 95: 3291-3295.
126. Olmos-Serrano JL, Corbin JG, Burns MP. 2011. The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome. Dev Neurosci 33: 395-403.
127. Osterweil EK, Krueger DD, Reinhold K, Bear MF. 2010. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci 30: 15616-15627.
128. Osterweil EK, Chuang SC, Chubykin AA, Sidorov M, Bianchi R, Wong RK, Bear MF. 2013. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77: 243-250.
129. Pacey LK, Heximer SP, Hampson DR. 2009. Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol 76: 18-24.
130. Pan L, Zhang YQ, Woodruff E, Broadie K. 2004. The Drosophila fragile X gene negatively regulates neuronal elaboration and synaptic differentiation. Curr Biol 14: 1863-1870.
131. Pan L, Woodruff E III, Liang P, Broadie K. 2008. Mechanistic relationships between Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A signaling. Mol Cell Neurosci 37: 747-760.
132. Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST. 1999. Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 94: 185-192.
133. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW. 2010. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 10: 91.
134. Pascual A, Preat T. 2001. Localization of long-term memory within the Drosophila mushroom body. Science 294: 1115-1117.
135. Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL. 2000. (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet 9: 1145-1159.
136. Penzes P, Cahill ME, Jones KA, Van Leeuwen JE, Woolfrey KM. 2011. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci 14: 285-293.
137. Phillips RG, LeDoux JE. 1992. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106: 274-285.
138. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL. 1991. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66: 817-822.
139. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, O'Dushlaine C, Chambert K, Bergen SE, Kahler A, et al. 2014. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506: 185-190.
140. Rajan NM. 2014. Speaking human. Tenn Med 107: 33.
141. Redondo RL, Morris RG. 2011. Making memories last: the synaptic tagging and capture hypothesis. Nat Rev Neurosci 12: 17-30.
142. Reeve SP, Bassetto L, Genova GK, Kleyner Y, Leyssen M, Jackson FR, Hassan BA. 2005. The Drosophila fragile X mental retardation protein controls actin dynamics by directly regulating profilin in the brain. Curr Biol 15: 1156-1163.
143. Renoux AJ, Sala-Hamrick KJ, Carducci NM, Frazer M, Halsey KE, Sutton MA, Dolan DF, Murphy GG, Todd PK. 2014. Impaired sensorimotor gating in Fmr1 knock out and Fragile X premutation model mice. Behav Brain Res 267C: 42-45.
144. Restivo L, Ferrari F, Passino E, Sgobio C, Bock J, Oostra BA, Bagni C, Ammassari-Teule M. 2005. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci 102: 11557-11562.
145. Rihs TA, Tomescu MI, Britz J, Rochas V, Custo A, Schneider M, Debbane M, Eliez S, Michel CM. 2013. Altered auditory processing in frontal and left temporal cortex in 22q11.2 deletion syndrome: a group at high genetic risk for schizophrenia. Psychiatry Res 212: 141-149.
146. Rogoz Z, Skuza G. 2011. Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats. Pharmacol Rep 63: 1547-1552.
147. Roman G, Davis RL. 2001. Molecular biology and anatomy of Drosophila olfactory associative learning. Bioessays 23: 571-581.
148. Ronesi JA, Collins KA, Hays SA, Tsai NP, Guo W, Birnbaum SG, Hu JH, Worley PF, Gibson JR, Huber KM. 2012. Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome. Nat Neurosci 15: 431-440, S431.
149. Rotschafer SE, Trujillo MS, Dansie LE, Ethell IM, Razak KA. 2012. Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome. Brain Res 1439: 7-14.
150. Roy S, Watkins N, Heck D. 2012. Comprehensive analysis of ultrasonic vocalizations in a mouse model of fragile X syndrome reveals limited, call type specific deficits. PLoS One 7: e44816.
151. Sala C, Segal M. 2014. Dendritic spines: the locus of structural and functional plasticity. Physiol Rev 94: 141-188.
152. Sanchez-Morla EM, Santos JL, Aparicio A, Garcia-Jimenez MA, Villanueva C, Martinez-Vizcaino V, Arango C. 2009. Antipsychotic effects on auditory sensory gating in schizophrenia patients. Eur Neuropsychopharmacol 19: 905-909.
153. Schenck A, Bardoni B, Langmann C, Harden N, Mandel JL, Giangrande A. 2003. CYFIP/Sra-1 controls neuronal connectivity in Drosophila and links the Rac1 GTPase pathway to the fragile X protein. Neuron 38: 887-898.
154. Sehgal A, Joiner W, Crocker A, Koh K, Sathyanarayanan S, Fang Y, Wu M, Williams JA, Zheng X. 2007. Molecular analysis of sleep: wake cycles in Drosophila. Cold Spring Harb Symp Quant Biol 72: 557-564.
155. Sekine T, Yamaguchi T, Hamano K, Siomi H, Saez L, Ishida N, Shimoda M. 2008. Circadian phenotypes of Drosophila fragile x mutants in alternative genetic backgrounds. Zoolog Sci 25: 561-571.
156. Sethna F, Moon C, Wang H. 2013. From FMRP function to potential therapies for fragile X syndrome. Neurochem Res. 39: 1016-1031.
157. Sherman SL. 2000. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 97: 189-194.
158. Siegel C, Waldo M, Mizner G, Adler LE, Freedman R. 1984. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses. Arch Gen Psychiatry 41: 607-612.
159. Siller SS, Broadie K. 2011. Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis Model Mech 4: 673-685.
160. Sofola O, Sundram V, Ng F, Kleyner Y, Morales J, Botas J, Jackson FR, Nelson DL. 2008. The Drosophila FMRP and LARK RNA-binding proteins function together to regulate eye development and circadian behavior. J Neurosci 28: 10200-10205.
161. Spencer CM, Alekseyenko O, Serysheva E, Yuva-Paylor LA, Paylor R. 2005. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav 4: 420-430.
162. Spencer CM, Serysheva E, Yuva-Paylor LA, Oostra BA, Nelson DL, Paylor R. 2006. Exaggerated behavioral phenotypes in Fmr1/Fxr2 double knockout mice reveal a functional genetic interaction between Fragile X-related proteins. Hum Mol Genet 15: 1984-1994.
163. Sun MK, Hongpaisan J, Lim C, Alkon DL. 2014. Bryostatin-1 restores hippocampal synapses and spatial learning and memory in adult fragile X mice. J Pharmacol Exp Ther 349: 393-401.
164. Suryavanshi PS, Ugale RR, Yilmazer-Hanke D, Stairs DJ, Dravid SM. 2014. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice. Br J Pharmacol 171: 799-809.
165. Tauber JM, Vanlandingham PA, Zhang B. 2011. Elevated levels of the vesicular monoamine transporter and a novel repetitive behavior in the Drosophila model of fragile X syndrome. PLoS One 6: e27100.
166. Tessier CR, Broadie K. 2008. Drosophila fragile X mental retardation protein developmentally regulates activity-dependent axon pruning. Development 135: 1547-1557.
167. Thomas AM, Bui N, Perkins JR, Yuva-Paylor LA, Paylor R. 2012. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology 219: 47-58.
168. Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, Musumeci S, Ramos FJ, Frontera M, Sorge G, et al. 2008. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A 146: 803-812.
169. Tully T. 1984. Drosophila learning: behavior and biochemistry. Behav Genet 14: 527-557.
170. Tully T, Quinn WG. 1985. Classical conditioning and retention in normal and mutant Drosophila melanogaster. J Comp Physiol A 157: 263-277.
171. Udagawa T, Farny NG, Jakovcevski M, Kaphzan H, Alarcon JM, Anilkumar S, Ivshina M, Hurt JA, Nagaoka K, Nalavadi VC, et al. 2013. Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology. Nat Med 19: 1473-1477.
172. Utari A, Chonchaiya W, Rivera SM, Schneider A, Hagerman RJ, Faradz SM, Ethell IM, Nguyen DV. 2010. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil 115: 433-443.
173. van Alphen B, Yap MH, Kirszenblat L, Kottler B, van Swinderen B. 2013. A dynamic deep sleep stage in Drosophila. J Neurosci 33: 6917-6927.
174. Van Dam D, D'Hooge R, Hauben E, Reyniers E, Gantois I, Bakker CE, Oostra BA, Kooy RF, De Deyn PP. 2000. Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice. Behav Brain Res 117: 127-136.
175. Veeraragavan S, Graham D, Bui N, Yuva-Paylor LA, Wess J, Paylor R. 2012. Genetic reduction of muscarinic M4 receptor modulates analgesic response and acoustic startle response in a mouse model of fragile X syndrome (FXS). Behav Brain Res 228: 1-8.
176. Ventura R, Pascucci T, Catania MV, Musumeci SA, Puglisi-Allegra S. 2004. Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: involvement of dopamine in the medial prefrontal cortex. Behav Pharmacol 15: 433-442.
177. Verheij C, Bakker CE, de Graaff E, Keulemans J, Willemsen R, Verkerk AJ, Galjaard H, Reuser AJ, Hoogeveen AT, Oostra BA. 1993. Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature 363: 722-724.
178. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP, et al. 1991. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65: 905-914.
179. Vinueza Veloz MF, Buijsen RA, Willemsen R, Cupido A, Bosman LW, Koekkoek SK, Potters JW, Oostra BA, De Zeeuw CI. 2012. The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice. Genes Brain Behav 11: 325-331.
180. Waltes R, Duketis E, Knapp M, Anney RJ, Huguet G, Schlitt S, Jarczok TA, Sachse M, Kampfer LM, Kleinbock T, et al. 2014. Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders. Hum Genet. 133: 781-792.
181. Wan L, Dockendorff TC, Jongens TA, Dreyfuss G. 2000. Characterization of dFMR1, a Drosophila melanogaster homolog of the fragile X mental retardation protein. Mol Cell Biol 20: 8536-8547.
182. Wang YC, Lin ML, Lin SJ, Li YC, Li SY. 1997. Novel point mutation within intron 10 of FMR-1 gene causing fragile X syndrome. Hum Mutat 10: 393-399.
183. Wang DO, Kim SM, Zhao Y, Hwang H, Miura SK, Sossin WS, Martin KC. 2009. Synapse- and stimulus-specific local translation during long-term neuronal plasticity. Science 324: 1536-1540.
184. Wang T, Bray SM, Warren ST. 2012. New perspectives on the biology of fragile X syndrome. Curr Opin Genet Dev 22: 256-263.
185. Weiler IJ, Spangler CC, Klintsova AY, Grossman AW, Kim SH, Bertaina-Anglade V, Khaliq H, de Vries FE, Lambers FA, Hatia F, et al. 2004. Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. Proc Natl Acad Sci 101: 17504-17509.
186. Westmark CJ, Westmark PR, O'Riordan KJ, Ray BC, Hervey CM, Salamat MS, Abozeid SH, Stein KM, Stodola LA, Tranfaglia M, et al. 2011. Reversal of fragile X phenotypes by manipulation of AbetaPP/Abeta levels in Fmr1KO mice. PLoS One 6: e26549.
187. Xu K, Bogert BA, Li W, Su K, Lee A, Gao FB. 2004. The fragile X-related gene affects the crawling behavior of Drosophila larvae by regulating the mRNA level of the DEG/ENaC protein pickpocket1. Curr Biol 14: 1025-1034.
188. Yamamoto D, Koganezawa M. 2013. Genes and circuits of courtship behaviour in Drosophila males. Nat Rev Neurosci 14: 681-692.
189. Yan QJ, Asafo-Adjei PK, Arnold HM, Brown RE, Bauchwitz RP. 2004. A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav 3: 337-359.
190. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. 2005. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49: 1053-1066.
191. Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS. 2010. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol 79: 632-646.
192. Zarnescu DC, Shan G, Warren ST, Jin P. 2005. Come FLY with us: toward understanding fragile X syndrome. Genes Brain Behav 4: 385-392.
193. Zhang YQ, Bailey AM, Matthies HJ, Renden RB, Smith MA, Speese SD, Rubin GM, Broadie K. 2001. Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell 107: 591-603.
194. Zhang J, Fang Z, Jud C, Vansteensel MJ, Kaasik K, Lee CC, Albrecht U, Tamanini F, Meijer JH, Oostra BA, et al. 2008. Fragile X-related proteins regulate mammalian circadian behavioral rhythms. Am J Hum Genet 83: 43-52.
195. Zhao L, Wang D, Wang Q, Rodal AA, Zhang YQ. 2013. Drosophila cyfip regulates synaptic development and endocytosis by suppressing filamentous actin assembly. PLoS Genet 9: e1003450.